Participants on weekly injections of 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, and 45.3% of participants achieved ≥ 30% weight loss.

The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from ...

The weight loss drug conversation has been accelerating for years – from the early Ozempic headlines through the Wegovy wave ...

Retatrutide demonstrated substantial dose-dependent improvements in waist circumference and crucial cardiovascular risk factors, including non-HDL-C, triglycerides, systolic blood pressure, and ...

Lilly met analysts’ sky-high expectations with 28.3% weight loss over 80 weeks for the triple hormone receptor agonist ...

Most people trying to lose significant weight eventually hit a wall. They’ve made the dietary changes, added the exercise, ...

iPercent change in the WOMAC pain subscale score and percent change in the WOMAC physical function subscale score were not pre-specified and were estimated from a post-hoc analysis.iiNot controlled ...

Eli Lilly's triple G agonist retatrutide has achieved weight loss of more than 28% in a new phase 3 trial that keeps it on ...

Top-line results from the phase III trial show average weight losses of 19% to 28.3% by 80 weeks depending on dose.